While the previous model, released in 2020, amazed the research community with its ability to predict proteins structures, researchers have been clamoring for the tool to handle more than just proteins. Now, DeepMind says, AlphaFold 3 can predict the structures of DNA, RNA, and molecules like ligands, which are essential to drug discovery. DeepMind says the tool provides a more nuanced and dynamic portrait of molecule interactions than anything previously available. "Biology is a dynamic system," DeepMind CEO Demis Hassabis told reporters on a call. "Properties of biology emerge through the interactions between different molecules in the cell, and you can think about AlphaFold 3 as our first big sort of step toward [modeling] that."

Two years ago, as the COVID-19 pandemic swept across the world, researchers at DeepMind, the artificial intelligence (AI) and research laboratory subsidiary of Alphabet Inc., demonstrated how it could use machine learning to achieve a breakthrough in the ability to predict how proteins, the work-horses of the living cell, fold into the intricate shapes they take on. The work gave hope to biologists that they could use this kind of tool to tackle diseases such as the SARS-CoV-2 coronavirus much more quickly in the future. Researchers were able to assess the abilities of DeepMind's AlphaFold2 thanks to its inclusion in the 14th Critical Assessment of Structure Prediction (CASP14), a benchmarking competition that ran through 2020 and which added a parallel program to uncover the structures of key proteins from the SARS-CoV2 virus to try to accelerate vaccine and drug development. The organizers of CASP14 declared the tool represented "an almost complete solution to the problem of computing three-dimensional structure from amino-acid sequences," though some caveats lie behind that statement. In principle, quantum mechanical simulations can predict which collection of folds leads to the lowest combined energy of all the chemical bonds in the shape and the water and other molecules around it.

Proteins are essential to life, supporting practically all its functions. They are large complex molecules made from chains of amino acids. What a protein does mostly depends on its unique 3D structure. Understanding what shapes proteins fold into is known as the'protein folding problem,' and has stood as a grand challenge in biology for the past 50 years. In a significant scientific advance, the artificial intelligence group DeepMind's latest version of the AI system AlphaFold has been detected to solve this grand challenge by the organisers of the biennial Critical Assessment of Protein Structure Prediction (CASP). This breakthrough demonstrates the impact AI can have on fundamental fields that explain and shape the world.

Proteins may be small and unassuming, but these molecules are essential for a variety of biological functions in all living organisms, including digestion, immune response and even intracellular communication. Consisting of long chains of smaller organic compounds called amino acids, the different functions of various proteins are determined by the way they fold up in three-dimensional space. Not surprisingly, the folded structures of these protein chains can get immensely complex, and scientists have yet to fully figure out the mysteries behind how and why certain proteins fold the way they do, and how diseases like Alzheimer's might be caused when they misfold. While using modern technologies like cryo-electron microscopes, nuclear magnetic resonance and X-ray crystallography can help us understand protein folding a little better, it's an unfortunately time-consuming and costly process. Accurately predicting the folded structures of proteins could be the key to unlocking many medical mysteries, and thanks to recent developments in integrating artificial intelligence in the field of computational biology, that slow process may very well be accelerated -- allowing us to discover or even design new and useful proteins.

There is an escalating race to get to the bottom of predicting the 3D structures of proteins from their amino-acid sequences. It would not be wrong if it is said that it is one of the biggest challenges that the biological world face. Here again, thanks to the new artificial intelligence (AI) who comes to the rescue. At the completion of last year, Google's AI firm DeepMind introduced an algorithm called AlphaFold, which merged two techniques that were evolving in the field and defeated established contestants in a competition on a protein-structure prediction by an unexpected margin. And this year, in April, a US researcher discovered an algorithm that practices an entirely different approach.

Predicting protein structures from their sequences would aid drug design.Credit: Edward Kinsman/Science Photo Library The race to crack one of biology's grandest challenges -- predicting the 3D structures of proteins from their amino-acid sequences -- is intensifying, thanks to new artificial-intelligence (AI) approaches. At the end of last year, Google's AI firm DeepMind debuted an algorithm called AlphaFold, which combined two techniques that were emerging in the field and beat established contenders in a competition on protein-structure prediction by a surprising margin. And in April this year, a US researcher revealed an algorithm that uses a totally different approach. He claims his AI is up to one million times faster at predicting structures than DeepMind's, although probably not as accurate in all situations. More broadly, biologists are wondering how else deep learning -- the AI technique used by both approaches -- might be applied to the prediction of protein arrangements, which ultimately dictate a protein's function.

Composed of long chains of amino acids, proteins perform these myriad tasks by folding themselves into precise 3D structures that govern how they interact with other molecules. Because a protein's shape determines its function and the extent of its dysfunction in disease, efforts to illuminate protein structures are central to all of molecular biology -- and in particular, therapeutic science and the development of lifesaving and life-altering medicines. In recent years, computational methods have made significant strides in predicting how proteins fold based on knowledge of their amino acid sequence. If fully realized, these methods have the potential to transform virtually all facets of biomedical research. Current approaches, however, are limited in the scale and scope of the proteins that can be determined.

Proteins are crucial to almost every fundamental biological process necessary for life. They do everything from create and maintain the shape of cells to serving as both signal and receiver for cellular communications. Proteins are composed on long chains of amino acids and they perform their varied tasks by folding themselves into precise 3D structures that determine how they function and interact with other molecules. Because their exact shape is so crucial to their function research into uncovering the exact shape is a central task to molecular biology. This task is especially important for the development of lifesaving and life-altering medicines.

It was with a strangely deflated feeling in his gut that Harvard biologist Mohammed AlQuraishi made his way to Cancun for a scientific conference in December. Strange because a major advance had just been made in his field, something that might normally make him happy. Deflated because the advance hadn't been made by him or by any of his fellow academic researchers. It had been made by a machine. DeepMind, an AI company that Google bought in 2014, had outperformed all the researchers who'd submitted entries to the Critical Assessment of Structure Prediction (CASP) conference, which is basically a fancy science contest for grown-ups. Every two years, researchers working on one of the biggest puzzles in biochemistry, known as the protein folding problem, try to prove how good their predictive powers are by submitting a prediction about the 3D shapes that certain proteins will take.

Researchers at DeepMind, owned by Google's parent company, are applying their powerful artificial intelligence systems to drug discovery research. Researchers at DeepMind, owned by Google's parent company, are applying their powerful artificial intelligence systems to drug discovery research. Researchers at DeepMind, owned by Google's parent company, are applying their powerful artificial intelligence systems to drug discovery research. Researchers at DeepMind, owned by Google's parent company, are applying their powerful artificial intelligence systems to drug discovery research. You can think of it as a World Cup of biochemical research.